APA (7th ed.) Citation

Katakami, N., Mita, T., Yoshii, H., Shiraiwa, T., Yasuda, T., Okada, Y., . . . Torimoto, K. (2023). Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: A 2-year extension study of the UTOPIA trial. Cardiovascular diabetology, 22(1), 143-15. https://doi.org/10.1186/s12933-023-01879-4

Chicago Style (17th ed.) Citation

Katakami, Naoto, et al. "Tofogliflozin Long-term Effects on Atherosclerosis Progression and Major Clinical Parameters in Patients with Type 2 Diabetes Mellitus Lacking a History of Cardiovascular Disease: A 2-year Extension Study of the UTOPIA Trial." Cardiovascular Diabetology 22, no. 1 (2023): 143-15. https://doi.org/10.1186/s12933-023-01879-4.

MLA (9th ed.) Citation

Katakami, Naoto, et al. "Tofogliflozin Long-term Effects on Atherosclerosis Progression and Major Clinical Parameters in Patients with Type 2 Diabetes Mellitus Lacking a History of Cardiovascular Disease: A 2-year Extension Study of the UTOPIA Trial." Cardiovascular Diabetology, vol. 22, no. 1, 2023, pp. 143-15, https://doi.org/10.1186/s12933-023-01879-4.